Summary:
A phase 3, randomized, observer-blinded study to evaluate the safety, tolerability, and immunogenicity of a combined Modified RNA vaccine candidate against covid-19 and influenza in healthy individuals.
Qualified Participants Must:
• Be between the ages of 18-64
•
Not have received COVID-19 shot within the last 6 months
•
Not have received Flu shot within the last 6 months
Qualified Participants May Receive:
$119/visits, 4 visits
$50 for completing all 7 e-diary entries